蛋白質穩定性分析市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、技術、最終用途、地區和競爭格局分類，2021-2031年）

全球蛋白質穩定性分析市場預計將從 2025 年的 33.5 億美元成長到 2031 年的 62.7 億美元，複合年成長率達到 11.01%。

此領域涵蓋用於評估蛋白質治療藥物在不同環境條件下結構完整性的調查方法。推動該市場發展的關鍵因素是製藥業日益關注複雜的生物製藥，這些製劑需要進行嚴格的穩定性分析，以確保藥物安全並符合監管要求。此外，對創新的大量投資也進一步刺激了這項需求。根據歐洲製藥工業協會聯合會 (EFPIA) 預測，到 2024 年，歐洲製藥業預計將在研發方面投入約 550 億歐元。這些投資凸顯了穩定性分析在降低高價值藥物開發專案風險方面發揮的關鍵作用。

然而，由於專業分析設備的高昂實施成本，市場面臨許多障礙。先進技術所需的大量資本投入限制了預算有限的中小型生物技術公司的進入。因此，此財務壁壘阻礙了綜合檢測解決方案的廣泛應用，並限制了市場擴張。

市場促進因素

生物製藥和生物製藥的快速發展是全球蛋白質穩定性分析市場的主要驅動力。隨著製藥業將重心從小分子藥物轉向單株抗體和重組蛋白等複雜的大分子治療藥物，對穩健的穩定性測試至關重要，以防止藥物在儲存和運輸過程中發生聚集，並確保其療效。越來越多的新生物製藥進入法規核准流程，也直接推動了這個趨勢。根據美國食品藥物管理局(FDA) 於 2024 年 1 月發布的《2023 年新藥核准情況報告》，該機構預計將在 2023 年核准55 種新療法，較上年度的37 種顯著增加。如此大量的新藥上市需要進行嚴格的分析測試以滿足安全通訊協定，從而擴大了穩定性分析服務和設備的市場需求。

同時，製藥和生物技術公司不斷增加的研發投入為先進穩定性測試解決方案的實施提供了必要的資金。高價值藥物開發專案需要先進的分析技術來評估蛋白質在壓力條件下的完整性，而各公司也正為這些品質保證措施分配大量預算。例如，根據強生公司於2024年1月發布的「2023會計年度全年業績」新聞稿，該公司報告稱，該會計年度的研發投入創下151億美元的紀錄。如此龐大的支出反映了整個產業財務實力推動技術創新的趨勢。此外，區域成長也凸顯了該產業強勁的財務狀況。根據瑞士生物技術協會於2024年4月發布的“2024年瑞士生物技術報告”，預計僅瑞士生物技術產業在2023年就將創造73億瑞士法郎的創紀錄收入，這證實了全球擁有大量資源來支持蛋白質穩定性分析等關鍵開發步驟。

市場挑戰

專業分析設備高昂的實施成本是全球蛋白質穩定性分析市場擴張的一大障礙。先進的穩定性分析需要精密的硬體，這需要大量的資本投入，從而對小規模的市場參與企業構成了很高的進入門檻。這種財務負擔對新興生技公司和學術研究機構的影響尤其顯著，因為它們的預算往往有限。因此，這些機構被迫推遲購買關鍵的內部測試設備，阻礙了先進穩定性分析解決方案的廣泛應用，並減緩了整體市場收入的成長。

生技產業面臨的動盪投資環境進一步加劇了這種經濟壓力。根據生技創新組織（BIO）的數據顯示，2025年第二季新興生技公司的Start-Ups資金大幅下降至9億美元，遠低於第一季的26億美元。資金的日益緊縮迫使中小企業優先考慮緊迫的臨床開發成本，而非基礎設施投資，這直接降低了它們購買高價值穩定性分析系統的能力。因此，市場面臨著來自這一重要客戶群的需求下降，限制了技術整合的廣泛應用，並阻礙了產業發展。

市場趨勢

將人工智慧融入預測穩定性建模正在從根本上改變生物製藥公司評估候選藥物的方式。借助先進的機器學習演算法，研究人員現在可以在物理測試開始之前，透過電腦模擬準確預測蛋白質分解途徑和聚集風險。這項能力顯著減少了早期開發所需的資源，並且能夠快速優先篩選出高度穩定的分子。業界對這項技術的投入也反映在定向資本注入。根據AI Proteins公司2025年11月發布的題為「AI Proteins完成A輪融資4150萬美元，推進全新微型蛋白開發作為新型治療方法」的新聞稿，該公司獲得了4150萬美元的資金籌措，用於加速其人工智慧驅動的穩定治療性微型蛋白設計平台。此類投資凸顯了向計算方法轉變的趨勢，旨在最大限度地降低後期臨床試驗的失敗率。

同時，隨著自動化實驗室工作流程的實施，穩定性測試的實際操作效率也日益提高。實驗室正在部署機器人液體處理系統和自動盤式分析儀，以處理複雜生物分析所需的大量樣本，從而消除人為誤差並提高數據可重複性。這種從手動流程向自動化流程的轉變對於維持現代研發中心的高通量能力至關重要。近期企業策略也顯著體現了這項基礎設施的擴展。根據阿斯特捷利康2024年11月發布的題為「投資35億美元用於美國研發和生產」的新聞稿，該公司宣布將投資35億美元用於擴大其研發規模，包括整合先進的自動化技術。這些自動化系統將確保蛋白質穩定性分析能夠跟上藥物研發加速發展的腳步。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球蛋白質穩定性分析市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（試劑及檢測試劑盒、設備、耗材及配件、軟體）
  • 透過技術（層析法、光譜法、表面等離子體共振成像（SPRI）、差示掃描量熱法（DSC）、差示掃描螢光（DSF）及其他）
  • 透過申請（製藥和生物技術公司、受託研究機構(CRO)、學術機構、研究機構）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美蛋白質穩定性分析市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲蛋白質穩定性分析市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區蛋白質穩定性分析市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲蛋白質穩定性分析市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美蛋白質穩定分析市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球蛋白質穩定性分析市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Unchained Labs
• ProtaGene US, Inc.
• Charles River Laboratories International, Inc.
• Intas Pharmaceuticals Ltd.
• Amgen Inc.
• Neurelis, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Enzo Biochem Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Protein Stability Analysis Market is projected to expand from USD 3.35 Billion in 2025 to USD 6.27 Billion by 2031, achieving a compound annual growth rate of 11.01%. This sector encompasses analytical methodologies utilized to evaluate the structural integrity of protein therapeutics across diverse environmental conditions. A primary force driving this market is the pharmaceutical industry's deepening focus on complex biologics, which necessitates rigorous stability profiling to guarantee drug safety and adhere to regulatory mandates. This demand is bolstered by significant financial commitments to innovation; according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the pharmaceutical sector invested an estimated €55,000 million in research and development within Europe in 2024. Such investment underscores the vital role of stability analysis in mitigating risks within high-value drug development programs.

However, the market faces a substantial obstacle due to the high acquisition costs associated with specialized analytical instrumentation. The significant capital expenditure required for advanced technologies restricts accessibility for smaller biotechnology enterprises operating with limited budgets. Consequently, this financial barrier hinders the widespread adoption of comprehensive testing solutions and constrains broader market expansion.

Market Driver

The surge in biopharmaceutical and biologics development serves as a primary catalyst for the Global Protein Stability Analysis Market. As the pharmaceutical industry shifts its focus from small-molecule drugs to complex large-molecule therapeutics, such as monoclonal antibodies and recombinant proteins, the requirement for robust stability testing becomes critical to prevent aggregation and ensure efficacy during storage and transport. This trend is directly evidenced by the increasing volume of novel biological entities entering the regulatory pipeline. According to the U.S. Food and Drug Administration's 'Novel Drug Approvals for 2023' report from January 2024, the agency approved 55 novel therapeutics in 2023, a significant rise from the 37 approvals recorded in the previous year. This influx necessitates rigorous analytical testing to satisfy safety protocols, thereby expanding the market for stability analysis services and instrumentation.

Concurrently, increasing R&D investments by pharmaceutical and biotechnology companies are providing the necessary capital to adopt advanced stability testing solutions. High-value drug development programs require sophisticated analytical technologies to assess protein integrity under stress conditions, prompting companies to allocate substantial budgets toward these quality assurance measures. For instance, according to Johnson & Johnson's 'Full Year 2023 Results' press release in January 2024, the company reported a record research and development investment of $15.1 billion for the fiscal year. This scale of spending reflects a broader industry pattern where financial health drives technical innovation. Furthermore, the sector's robust financial footing is highlighted by regional growth; according to the Swiss Biotech Association's 'Swiss Biotech Report 2024' from April 2024, the Swiss biotechnology industry alone generated a record revenue of CHF 7.3 billion in 2023, underscoring the massive global resources available to support essential development phases like protein stability analysis.

Market Challenge

The high acquisition costs associated with specialized analytical instrumentation constitute a significant impediment to the expansion of the Global Protein Stability Analysis Market. Advanced stability profiling requires precise hardware that commands substantial capital expenditure, creating a steep barrier to entry for smaller market participants. This financial burden disproportionately affects emerging biotechnology companies and academic research institutions, which often operate under restricted budgets. Consequently, these organizations are frequently compelled to defer the purchase of essential in-house testing equipment, thereby stifling the broader adoption of advanced stability analysis solutions and slowing overall market revenue growth.

This economic pressure is significantly exacerbated by the volatile investment climate currently facing the biotechnology sector. According to the Biotechnology Innovation Organization (BIO), in 2025, startup funding for emerging biotech companies declined sharply to $900 million in the second quarter, down from $2.6 billion in the first quarter. Such a contraction in available capital forces smaller enterprises to prioritize immediate clinical development expenses over infrastructure investments, directly reducing their capacity to procure high-value stability analysis systems. As a result, the market faces reduced demand from this critical customer segment, limiting the potential for widespread technological integration and hampering sector progress.

Market Trends

The Integration of Artificial Intelligence for Predictive Stability Modeling is fundamentally reshaping how biopharmaceutical companies assess drug candidates. By leveraging advanced machine learning algorithms, researchers can now accurately forecast protein degradation pathways and aggregation risks in silico before physical testing begins. This capability significantly reduces the resources required for early-stage development, allowing for the rapid prioritization of stable molecules. The sector's commitment to this technology is evident in targeted capital injections; according to AI Proteins' press release 'AI Proteins Raises $41.5M Series A Financing to Advance De Novo Miniproteins as a New Therapeutic Modality' in November 2025, the biotechnology company secured $41.5 million in funding specifically to accelerate its AI-driven platform for designing stable therapeutic miniproteins. Such investment underscores the shift toward computational methods that minimize failure rates in late-stage studies.

Concurrently, the Implementation of Automated Laboratory Workflows is streamlining the physical execution of stability testing. Laboratories are deploying robotic liquid handling systems and automated plate readers to manage the high volume of samples required for complex biologic profiling, thereby eliminating human error and enhancing data reproducibility. This transition from manual to automated processes is critical for maintaining high-throughput capabilities in modern R&D centers. This infrastructure expansion is highlighted by recent corporate strategies; according to AstraZeneca's 'AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States' press release in November 2024, the company announced a $3.5 billion capital investment focused on expanding its research footprint, which includes the integration of advanced automation technologies. These automated systems ensure that protein stability analysis keeps pace with the accelerating speed of drug discovery.

Key Market Players

• Unchained Labs
• ProtaGene US, Inc.
• Charles River Laboratories International, Inc.
• Intas Pharmaceuticals Ltd.
• Amgen Inc.
• Neurelis, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Enzo Biochem Inc.

Report Scope

In this report, the Global Protein Stability Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Stability Analysis Market, By Product

• Reagents and Assay Kits
• Instruments
• Consumable and Accessories
• Software

Protein Stability Analysis Market, By Technique

• Chromatography
• Spectroscopy
• Surface Plasma Resonance Imaging (SPRI)
• Differential Scanning Calorimetry (DSC)
• Differential Scanning Fluorimetry (DSF)
• Others

Protein Stability Analysis Market, By End Use

• Pharmaceutical and Biotechnology Companies
• Contract Research Organization
• Academic
• Research Institutes

Protein Stability Analysis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Stability Analysis Market.

Available Customizations:

Global Protein Stability Analysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Stability Analysis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Reagents and Assay Kits, Instruments, Consumable and Accessories, Software)
  • 5.2.2. By Technique (Chromatography, Spectroscopy, Surface Plasma Resonance Imaging (SPRI), Differential Scanning Calorimetry (DSC), Differential Scanning Fluorimetry (DSF), Others)
  • 5.2.3. By End Use (Pharmaceutical and Biotechnology Companies, Contract Research Organization, Academic, Research Institutes)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Protein Stability Analysis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technique
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protein Stability Analysis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Protein Stability Analysis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Protein Stability Analysis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By End Use

7. Europe Protein Stability Analysis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technique
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protein Stability Analysis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Protein Stability Analysis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Protein Stability Analysis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Protein Stability Analysis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Protein Stability Analysis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By End Use

8. Asia Pacific Protein Stability Analysis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technique
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protein Stability Analysis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Protein Stability Analysis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Protein Stability Analysis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Protein Stability Analysis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Protein Stability Analysis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Protein Stability Analysis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technique
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protein Stability Analysis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Protein Stability Analysis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Protein Stability Analysis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By End Use

10. South America Protein Stability Analysis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technique
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protein Stability Analysis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Protein Stability Analysis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Protein Stability Analysis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protein Stability Analysis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Unchained Labs
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ProtaGene US, Inc.
• 15.3. Charles River Laboratories International, Inc.
• 15.4. Intas Pharmaceuticals Ltd.
• 15.5. Amgen Inc.
• 15.6. Neurelis, Inc.
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Agilent Technologies, Inc.
• 15.9. PerkinElmer Inc.
• 15.10. Enzo Biochem Inc.

16. Strategic Recommendations

17. About Us & Disclaimer